A Varegacestat Hepatic Impairment Study
← catalyst calendarSponsored by Immunome, Inc. (industry) · IMNM — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Other
Enrollment
35actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-07 | actual | When the study began enrolling |
| Primary completion | 2025-11-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-06 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteer
- Hepatic Impairment (HI)
Intervention
- Drug: varegacestat
Primary outcomes
what the primary-completion date above is the date OFPK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.
measured Up to 4 weeks
PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.
measured Up to 4 weeks
PK of varegacestat and metabolite from a single oral dose of varegacestat in hepatic impaired adult participants to matched healthy adult participants.
measured Up to 4 weeks
Permalink · IMNM's whole pipeline · Catalyst calendar · Every registered study · What changed